

Healthy Volunteers

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

Trial Status Active, not recruiting	Trial Runs In 1 Country	Trial Identifier NCT06835465 GP45718
---	-----------------------------------	--

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Subjects

Trial Summary:

This is a phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of rifampin on the pharmacokinetics (PK) and safety of divarasib in healthy participants.

Genentech, Inc. Sponsor	Phase 1 Phase
NCT06835465 GP45718 Trial Identifiers	

Eligibility Criteria:

Gender All	Age #18 Years & # 60 Years	Healthy Volunteers Accepts Healthy Volunteers
----------------------	--------------------------------------	---

Inclusion Criteria:

- Males or females of non-childbearing potential
- Within body mass index (BMI) range of 18.0 to 32.0 kg/m2, inclusive

Exclusion Criteria:

ForPatients

by Roche

- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
- Poor peripheral venous access